nodes	percent_of_prediction	percent_of_DWPC	metapath
Tasosartan—AGTR2—cardiovascular system—metabolic syndrome X	0.082	0.192	CbGeAlD
Tasosartan—AGTR2—kidney—metabolic syndrome X	0.0803	0.188	CbGeAlD
Tasosartan—AGTR2—ACE Inhibitor Pathway—ACE—metabolic syndrome X	0.0582	0.104	CbGpPWpGaD
Tasosartan—AGTR1—artery—metabolic syndrome X	0.0528	0.124	CbGeAlD
Tasosartan—AGTR2—liver—metabolic syndrome X	0.0507	0.119	CbGeAlD
Tasosartan—AGTR1—endothelium—metabolic syndrome X	0.0446	0.105	CbGeAlD
Tasosartan—AGTR1—blood vessel—metabolic syndrome X	0.0412	0.0966	CbGeAlD
Tasosartan—AGTR2—ACE Inhibitor Pathway—AGT—metabolic syndrome X	0.0369	0.0657	CbGpPWpGaD
Tasosartan—AGTR2—ACE Inhibitor Pathway—NOS3—metabolic syndrome X	0.0271	0.0482	CbGpPWpGaD
Tasosartan—AGTR1—ACE Inhibitor Pathway—ACE—metabolic syndrome X	0.019	0.0338	CbGpPWpGaD
Tasosartan—AGTR1—cardiovascular system—metabolic syndrome X	0.0184	0.0431	CbGeAlD
Tasosartan—AGTR1—kidney—metabolic syndrome X	0.018	0.0421	CbGeAlD
Tasosartan—AGTR2—ACE Inhibitor Pathway—TGFB1—metabolic syndrome X	0.0179	0.0319	CbGpPWpGaD
Tasosartan—AGTR1—adipose tissue—metabolic syndrome X	0.0162	0.038	CbGeAlD
Tasosartan—CYP3A4—Liver X Receptor Pathway—NR1H3—metabolic syndrome X	0.0129	0.0229	CbGpPWpGaD
Tasosartan—AGTR1—ACE Inhibitor Pathway—AGT—metabolic syndrome X	0.012	0.0214	CbGpPWpGaD
Tasosartan—CYP3A4—Liver X Receptor Pathway—SCD—metabolic syndrome X	0.0114	0.0203	CbGpPWpGaD
Tasosartan—AGTR1—liver—metabolic syndrome X	0.0114	0.0266	CbGeAlD
Tasosartan—AGTR2—G alpha (i) signalling events—MTNR1B—metabolic syndrome X	0.00996	0.0177	CbGpPWpGaD
Tasosartan—AGTR2—GPCRs, Class A Rhodopsin-like—MTNR1B—metabolic syndrome X	0.00924	0.0165	CbGpPWpGaD
Tasosartan—AGTR1—ACE Inhibitor Pathway—NOS3—metabolic syndrome X	0.00883	0.0157	CbGpPWpGaD
Tasosartan—AGTR2—Peptide ligand-binding receptors—GHRL—metabolic syndrome X	0.00872	0.0155	CbGpPWpGaD
Tasosartan—AGTR1—Arf6 trafficking events—SLC2A4—metabolic syndrome X	0.00794	0.0141	CbGpPWpGaD
Tasosartan—AGTR2—Class A/1 (Rhodopsin-like receptors)—MTNR1B—metabolic syndrome X	0.00792	0.0141	CbGpPWpGaD
Tasosartan—CYP3A4—Tamoxifen metabolism—FMO3—metabolic syndrome X	0.00771	0.0137	CbGpPWpGaD
Tasosartan—AGTR2—GPCRs, Class A Rhodopsin-like—HTR2C—metabolic syndrome X	0.0072	0.0128	CbGpPWpGaD
Tasosartan—AGTR2—G alpha (i) signalling events—CNR1—metabolic syndrome X	0.00696	0.0124	CbGpPWpGaD
Tasosartan—CYP3A4—kidney—metabolic syndrome X	0.0066	0.0155	CbGeAlD
Tasosartan—AGTR2—GPCRs, Class A Rhodopsin-like—CNR1—metabolic syndrome X	0.00646	0.0115	CbGpPWpGaD
Tasosartan—AGTR2—Peptide ligand-binding receptors—CCL5—metabolic syndrome X	0.0064	0.0114	CbGpPWpGaD
Tasosartan—AGTR2—Class A/1 (Rhodopsin-like receptors)—HTR2C—metabolic syndrome X	0.00617	0.011	CbGpPWpGaD
Tasosartan—CYP3A4—Drug Induction of Bile Acid Pathway—NR1I3—metabolic syndrome X	0.00617	0.011	CbGpPWpGaD
Tasosartan—AGTR2—GPCR ligand binding—MTNR1B—metabolic syndrome X	0.00603	0.0107	CbGpPWpGaD
Tasosartan—AGTR2—Class A/1 (Rhodopsin-like receptors)—GHRL—metabolic syndrome X	0.00585	0.0104	CbGpPWpGaD
Tasosartan—AGTR1—ACE Inhibitor Pathway—TGFB1—metabolic syndrome X	0.00584	0.0104	CbGpPWpGaD
Tasosartan—CYP3A4—Liver X Receptor Pathway—SREBF1—metabolic syndrome X	0.00571	0.0102	CbGpPWpGaD
Tasosartan—CYP3A4—Drug Induction of Bile Acid Pathway—NR1I2—metabolic syndrome X	0.00564	0.01	CbGpPWpGaD
Tasosartan—AGTR2—Class A/1 (Rhodopsin-like receptors)—CNR1—metabolic syndrome X	0.00554	0.00986	CbGpPWpGaD
Tasosartan—Losartan—ACE—metabolic syndrome X	0.00542	0.445	CrCbGaD
Tasosartan—AGTR2—G alpha (i) signalling events—CCL5—metabolic syndrome X	0.0054	0.00961	CbGpPWpGaD
Tasosartan—AGTR2—Peptide ligand-binding receptors—AGT—metabolic syndrome X	0.00535	0.00953	CbGpPWpGaD
Tasosartan—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1H3—metabolic syndrome X	0.00484	0.00862	CbGpPWpGaD
Tasosartan—AGTR2—GPCR ligand binding—HTR2C—metabolic syndrome X	0.0047	0.00836	CbGpPWpGaD
Tasosartan—Valsartan—ALB—metabolic syndrome X	0.00455	0.373	CrCbGaD
Tasosartan—AGTR2—G alpha (i) signalling events—AGT—metabolic syndrome X	0.00451	0.00804	CbGpPWpGaD
Tasosartan—AGTR1—Arf6 trafficking events—INS—metabolic syndrome X	0.00446	0.00795	CbGpPWpGaD
Tasosartan—AGTR2—GPCR ligand binding—GHRL—metabolic syndrome X	0.00445	0.00793	CbGpPWpGaD
Tasosartan—AGTR2—Peptide ligand-binding receptors—CCL2—metabolic syndrome X	0.00441	0.00785	CbGpPWpGaD
Tasosartan—AGTR2—Class A/1 (Rhodopsin-like receptors)—CCL5—metabolic syndrome X	0.00429	0.00764	CbGpPWpGaD
Tasosartan—AGTR2—GPCR ligand binding—CNR1—metabolic syndrome X	0.00422	0.00751	CbGpPWpGaD
Tasosartan—CYP3A4—liver—metabolic syndrome X	0.00417	0.00978	CbGeAlD
Tasosartan—AGTR1—Angiopoietin receptor Tie2-mediated signaling—NOS3—metabolic syndrome X	0.00372	0.00663	CbGpPWpGaD
Tasosartan—CYP3A4—Constitutive Androstane Receptor Pathway—NR1I3—metabolic syndrome X	0.00372	0.00662	CbGpPWpGaD
Tasosartan—AGTR2—Class A/1 (Rhodopsin-like receptors)—AGT—metabolic syndrome X	0.00359	0.00639	CbGpPWpGaD
Tasosartan—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I3—metabolic syndrome X	0.00354	0.00631	CbGpPWpGaD
Tasosartan—AGTR2—GPCR downstream signaling—MTNR1B—metabolic syndrome X	0.00341	0.00607	CbGpPWpGaD
Tasosartan—AGTR2—GPCR ligand binding—CCL5—metabolic syndrome X	0.00327	0.00582	CbGpPWpGaD
Tasosartan—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—metabolic syndrome X	0.00324	0.00577	CbGpPWpGaD
Tasosartan—AGTR2—Signaling by GPCR—MTNR1B—metabolic syndrome X	0.00309	0.00551	CbGpPWpGaD
Tasosartan—AGTR1—G alpha (q) signalling events—HTR2C—metabolic syndrome X	0.00303	0.0054	CbGpPWpGaD
Tasosartan—AGTR1—GPCRs, Class A Rhodopsin-like—MTNR1B—metabolic syndrome X	0.00301	0.00536	CbGpPWpGaD
Tasosartan—AGTR2—Class A/1 (Rhodopsin-like receptors)—CCL2—metabolic syndrome X	0.00296	0.00526	CbGpPWpGaD
Tasosartan—AGTR1—G alpha (q) signalling events—GHRL—metabolic syndrome X	0.00288	0.00512	CbGpPWpGaD
Tasosartan—CYP3A4—Aflatoxin activation and detoxification—GGT1—metabolic syndrome X	0.00287	0.00511	CbGpPWpGaD
Tasosartan—AGTR1—Peptide ligand-binding receptors—GHRL—metabolic syndrome X	0.00284	0.00506	CbGpPWpGaD
Tasosartan—AGTR2—GPCR ligand binding—AGT—metabolic syndrome X	0.00273	0.00487	CbGpPWpGaD
Tasosartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2C—metabolic syndrome X	0.00271	0.00483	CbGpPWpGaD
Tasosartan—CYP3A4—Phase 1 - Functionalization of compounds—FMO3—metabolic syndrome X	0.0027	0.00481	CbGpPWpGaD
Tasosartan—AGTR2—GPCR downstream signaling—HTR2C—metabolic syndrome X	0.00265	0.00473	CbGpPWpGaD
Tasosartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—MTNR1B—metabolic syndrome X	0.00258	0.00459	CbGpPWpGaD
Tasosartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—GHRL—metabolic syndrome X	0.00257	0.00458	CbGpPWpGaD
Tasosartan—AGTR2—GPCR downstream signaling—GHRL—metabolic syndrome X	0.00252	0.00448	CbGpPWpGaD
Tasosartan—AGTR2—Signaling by GPCR—HTR2C—metabolic syndrome X	0.00241	0.00429	CbGpPWpGaD
Tasosartan—AGTR2—GPCR downstream signaling—CNR1—metabolic syndrome X	0.00238	0.00424	CbGpPWpGaD
Tasosartan—AGTR1—GPCRs, Class A Rhodopsin-like—HTR2C—metabolic syndrome X	0.00235	0.00418	CbGpPWpGaD
Tasosartan—AGTR1—Angiopoietin receptor Tie2-mediated signaling—TNF—metabolic syndrome X	0.0023	0.0041	CbGpPWpGaD
Tasosartan—AGTR2—Signaling by GPCR—GHRL—metabolic syndrome X	0.00228	0.00407	CbGpPWpGaD
Tasosartan—AGTR2—GPCR ligand binding—CCL2—metabolic syndrome X	0.00225	0.00401	CbGpPWpGaD
Tasosartan—Losartan—ALB—metabolic syndrome X	0.00222	0.182	CrCbGaD
Tasosartan—AGTR2—Signaling by GPCR—CNR1—metabolic syndrome X	0.00216	0.00385	CbGpPWpGaD
Tasosartan—AGTR1—GPCRs, Class A Rhodopsin-like—CNR1—metabolic syndrome X	0.00211	0.00375	CbGpPWpGaD
Tasosartan—AGTR1—Peptide ligand-binding receptors—CCL5—metabolic syndrome X	0.00208	0.00371	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—HDAC3—metabolic syndrome X	0.00204	0.00364	CbGpPWpGaD
Tasosartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—HTR2C—metabolic syndrome X	0.00201	0.00358	CbGpPWpGaD
Tasosartan—AGTR1—GPCR ligand binding—MTNR1B—metabolic syndrome X	0.00196	0.0035	CbGpPWpGaD
Tasosartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—GHRL—metabolic syndrome X	0.0019	0.00339	CbGpPWpGaD
Tasosartan—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCA1—metabolic syndrome X	0.00186	0.00331	CbGpPWpGaD
Tasosartan—AGTR2—GPCR downstream signaling—CCL5—metabolic syndrome X	0.00185	0.00329	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—MTNR1B—metabolic syndrome X	0.00183	0.00325	CbGpPWpGaD
Tasosartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—CNR1—metabolic syndrome X	0.0018	0.00321	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—RBP4—metabolic syndrome X	0.00178	0.00317	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—TRIB3—metabolic syndrome X	0.00178	0.00317	CbGpPWpGaD
Tasosartan—AGTR1—G alpha (q) signalling events—AGT—metabolic syndrome X	0.00177	0.00315	CbGpPWpGaD
Tasosartan—AGTR1—Peptide ligand-binding receptors—AGT—metabolic syndrome X	0.00174	0.00311	CbGpPWpGaD
Tasosartan—AGTR1—Angiopoietin receptor Tie2-mediated signaling—AKT1—metabolic syndrome X	0.00171	0.00305	CbGpPWpGaD
Tasosartan—AGTR1—Allograft Rejection—TGFB1—metabolic syndrome X	0.00171	0.00304	CbGpPWpGaD
Tasosartan—AGTR2—Signaling by GPCR—CCL5—metabolic syndrome X	0.00168	0.00299	CbGpPWpGaD
Tasosartan—AGTR2—Signaling by GPCR—PLA2G4A—metabolic syndrome X	0.00167	0.00297	CbGpPWpGaD
Tasosartan—AGTR1—Allograft Rejection—TNF—metabolic syndrome X	0.00159	0.00284	CbGpPWpGaD
Tasosartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—AGT—metabolic syndrome X	0.00158	0.00281	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—APOC3—metabolic syndrome X	0.00158	0.00281	CbGpPWpGaD
Tasosartan—AGTR2—GPCR downstream signaling—AGT—metabolic syndrome X	0.00154	0.00275	CbGpPWpGaD
Tasosartan—AGTR1—GPCR ligand binding—HTR2C—metabolic syndrome X	0.00153	0.00273	CbGpPWpGaD
Tasosartan—AGTR1—GPCR ligand binding—GHRL—metabolic syndrome X	0.00145	0.00258	CbGpPWpGaD
Tasosartan—AGTR1—Peptide ligand-binding receptors—CCL2—metabolic syndrome X	0.00144	0.00256	CbGpPWpGaD
Tasosartan—CYP3A4—Biological oxidations—FMO3—metabolic syndrome X	0.00143	0.00255	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—HTR2C—metabolic syndrome X	0.00142	0.00254	CbGpPWpGaD
Tasosartan—CYP3A4—Metapathway biotransformation—FMO3—metabolic syndrome X	0.00141	0.00252	CbGpPWpGaD
Tasosartan—AGTR2—Signaling by GPCR—AGT—metabolic syndrome X	0.0014	0.0025	CbGpPWpGaD
Tasosartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—CCL5—metabolic syndrome X	0.0014	0.00249	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—CYBA—metabolic syndrome X	0.00138	0.00246	CbGpPWpGaD
Tasosartan—AGTR1—GPCR ligand binding—CNR1—metabolic syndrome X	0.00137	0.00245	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—GHRL—metabolic syndrome X	0.00135	0.0024	CbGpPWpGaD
Tasosartan—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARA—metabolic syndrome X	0.00129	0.0023	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—CNR1—metabolic syndrome X	0.00128	0.00228	CbGpPWpGaD
Tasosartan—CYP3A4—Metapathway biotransformation—EPHX2—metabolic syndrome X	0.00126	0.00224	CbGpPWpGaD
Tasosartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—AGT—metabolic syndrome X	0.00117	0.00208	CbGpPWpGaD
Tasosartan—AGTR2—Signaling by GPCR—CCL2—metabolic syndrome X	0.00116	0.00206	CbGpPWpGaD
Tasosartan—AGTR1—GPCR downstream signaling—MTNR1B—metabolic syndrome X	0.00111	0.00198	CbGpPWpGaD
Tasosartan—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—metabolic syndrome X	0.00107	0.0019	CbGpPWpGaD
Tasosartan—AGTR1—GPCR ligand binding—CCL5—metabolic syndrome X	0.00106	0.0019	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—IGF2—metabolic syndrome X	0.00104	0.00186	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—APOB—metabolic syndrome X	0.00101	0.00181	CbGpPWpGaD
Tasosartan—AGTR1—Signaling by GPCR—MTNR1B—metabolic syndrome X	0.00101	0.0018	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—CCL5—metabolic syndrome X	0.000991	0.00176	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—PLA2G4A—metabolic syndrome X	0.000987	0.00176	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—LPL—metabolic syndrome X	0.000969	0.00173	CbGpPWpGaD
Tasosartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—CCL2—metabolic syndrome X	0.000963	0.00172	CbGpPWpGaD
Tasosartan—AGTR1—GPCR ligand binding—AGT—metabolic syndrome X	0.000891	0.00159	CbGpPWpGaD
Tasosartan—AGTR1—GPCR downstream signaling—HTR2C—metabolic syndrome X	0.000865	0.00154	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—AGT—metabolic syndrome X	0.000829	0.00148	CbGpPWpGaD
Tasosartan—AGTR1—GPCR downstream signaling—GHRL—metabolic syndrome X	0.00082	0.00146	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—APOE—metabolic syndrome X	0.000812	0.00145	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—LEP—metabolic syndrome X	0.000812	0.00145	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—APOA1—metabolic syndrome X	0.000803	0.00143	CbGpPWpGaD
Tasosartan—AGTR1—Signaling by GPCR—HTR2C—metabolic syndrome X	0.000785	0.0014	CbGpPWpGaD
Tasosartan—AGTR1—GPCR downstream signaling—CNR1—metabolic syndrome X	0.000776	0.00138	CbGpPWpGaD
Tasosartan—AGTR1—Signaling by GPCR—GHRL—metabolic syndrome X	0.000744	0.00133	CbGpPWpGaD
Tasosartan—AGTR1—GPCR ligand binding—CCL2—metabolic syndrome X	0.000733	0.00131	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—IRS1—metabolic syndrome X	0.000724	0.00129	CbGpPWpGaD
Tasosartan—AGTR1—Signaling by GPCR—CNR1—metabolic syndrome X	0.000705	0.00126	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—INS—metabolic syndrome X	0.000694	0.00124	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—CCL2—metabolic syndrome X	0.000682	0.00122	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—IGF1—metabolic syndrome X	0.000671	0.00119	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—HDAC3—metabolic syndrome X	0.000666	0.00119	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—SERPINE1—metabolic syndrome X	0.000637	0.00113	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—NOS3—metabolic syndrome X	0.000608	0.00108	CbGpPWpGaD
Tasosartan—AGTR1—GPCR downstream signaling—CCL5—metabolic syndrome X	0.000602	0.00107	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—MTNR1B—metabolic syndrome X	0.000595	0.00106	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—TRIB3—metabolic syndrome X	0.00058	0.00103	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—RBP4—metabolic syndrome X	0.00058	0.00103	CbGpPWpGaD
Tasosartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—metabolic syndrome X	0.000578	0.00103	CbGpPWpGaD
Tasosartan—AGTR1—Signaling by GPCR—CCL5—metabolic syndrome X	0.000546	0.000973	CbGpPWpGaD
Tasosartan—AGTR1—Signaling by GPCR—PLA2G4A—metabolic syndrome X	0.000544	0.000969	CbGpPWpGaD
Tasosartan—AGTR2—GPCR downstream signaling—AKT1—metabolic syndrome X	0.000521	0.000928	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—APOC3—metabolic syndrome X	0.000514	0.000915	CbGpPWpGaD
Tasosartan—AGTR2—Signaling by GPCR—IL6—metabolic syndrome X	0.000513	0.000914	CbGpPWpGaD
Tasosartan—AGTR1—GPCR downstream signaling—AGT—metabolic syndrome X	0.000503	0.000896	CbGpPWpGaD
Tasosartan—CYP3A4—Biological oxidations—GGT1—metabolic syndrome X	0.000493	0.000877	CbGpPWpGaD
Tasosartan—AGTR2—Signaling by GPCR—AKT1—metabolic syndrome X	0.000473	0.000843	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—HTR2C—metabolic syndrome X	0.000464	0.000826	CbGpPWpGaD
Tasosartan—AGTR1—Signaling by GPCR—AGT—metabolic syndrome X	0.000457	0.000814	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—CYBA—metabolic syndrome X	0.000449	0.0008	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—GHRL—metabolic syndrome X	0.00044	0.000783	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—CNR1—metabolic syndrome X	0.000416	0.000742	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—TGFB1—metabolic syndrome X	0.000402	0.000716	CbGpPWpGaD
Tasosartan—AGTR1—Signaling by GPCR—CCL2—metabolic syndrome X	0.000376	0.00067	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—IGF2—metabolic syndrome X	0.00034	0.000606	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—APOB—metabolic syndrome X	0.000331	0.000589	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—CCL5—metabolic syndrome X	0.000323	0.000575	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—PLA2G4A—metabolic syndrome X	0.000322	0.000573	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—LPL—metabolic syndrome X	0.000316	0.000562	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—IL6—metabolic syndrome X	0.000303	0.00054	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—AKT1—metabolic syndrome X	0.00028	0.000498	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—AGT—metabolic syndrome X	0.00027	0.000481	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—LEP—metabolic syndrome X	0.000265	0.000471	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—APOE—metabolic syndrome X	0.000265	0.000471	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—APOA1—metabolic syndrome X	0.000262	0.000466	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—FMO3—metabolic syndrome X	0.000245	0.000437	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—IRS1—metabolic syndrome X	0.000236	0.00042	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—INS—metabolic syndrome X	0.000226	0.000403	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—CCL2—metabolic syndrome X	0.000222	0.000396	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—IGF1—metabolic syndrome X	0.000219	0.000389	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—EPHX2—metabolic syndrome X	0.000218	0.000389	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—MLXIPL—metabolic syndrome X	0.000218	0.000389	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—SERPINE1—metabolic syndrome X	0.000208	0.00037	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—G6PC2—metabolic syndrome X	0.000205	0.000366	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—NOS3—metabolic syndrome X	0.000198	0.000353	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—FABP4—metabolic syndrome X	0.000175	0.000311	CbGpPWpGaD
Tasosartan—AGTR1—GPCR downstream signaling—AKT1—metabolic syndrome X	0.00017	0.000302	CbGpPWpGaD
Tasosartan—AGTR1—Signaling by GPCR—IL6—metabolic syndrome X	0.000167	0.000298	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—HSD11B1—metabolic syndrome X	0.000166	0.000295	CbGpPWpGaD
Tasosartan—AGTR1—Signaling by GPCR—AKT1—metabolic syndrome X	0.000154	0.000275	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—G6PD—metabolic syndrome X	0.000148	0.000263	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—HDAC3—metabolic syndrome X	0.000144	0.000257	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—LPA—metabolic syndrome X	0.000141	0.000251	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—GCKR—metabolic syndrome X	0.000141	0.000251	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—PLA2G6—metabolic syndrome X	0.000136	0.000243	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—APOA5—metabolic syndrome X	0.000135	0.00024	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—TGFB1—metabolic syndrome X	0.000131	0.000233	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—TRIB3—metabolic syndrome X	0.000125	0.000223	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—NAMPT—metabolic syndrome X	0.000113	0.0002	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—LIPC—metabolic syndrome X	0.000112	0.000199	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—GCK—metabolic syndrome X	0.000112	0.000199	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—APOC3—metabolic syndrome X	0.000111	0.000198	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—CETP—metabolic syndrome X	0.000108	0.000192	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—SCARB1—metabolic syndrome X	0.000103	0.000184	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—SREBF1—metabolic syndrome X	0.0001	0.000179	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—IL6—metabolic syndrome X	9.88e-05	0.000176	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—HMGCR—metabolic syndrome X	9.76e-05	0.000174	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—GOT2—metabolic syndrome X	9.76e-05	0.000174	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—AKT1—metabolic syndrome X	9.11e-05	0.000162	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—ABCA1—metabolic syndrome X	8.7e-05	0.000155	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—SLC2A4—metabolic syndrome X	8.7e-05	0.000155	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—GOT1—metabolic syndrome X	8.42e-05	0.00015	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—GGT1—metabolic syndrome X	8.42e-05	0.00015	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—APOB—metabolic syndrome X	7.15e-05	0.000127	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—PLA2G4A—metabolic syndrome X	6.95e-05	0.000124	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—LPL—metabolic syndrome X	6.82e-05	0.000122	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—CD36—metabolic syndrome X	6.48e-05	0.000115	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—PPARA—metabolic syndrome X	6.03e-05	0.000107	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—AGT—metabolic syndrome X	5.84e-05	0.000104	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—APOE—metabolic syndrome X	5.72e-05	0.000102	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—APOA1—metabolic syndrome X	5.66e-05	0.000101	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—PPARG—metabolic syndrome X	4.98e-05	8.87e-05	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—INS—metabolic syndrome X	4.89e-05	8.7e-05	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—ALB—metabolic syndrome X	4.48e-05	7.98e-05	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—NOS3—metabolic syndrome X	4.29e-05	7.63e-05	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—PTGS2—metabolic syndrome X	3.92e-05	6.98e-05	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—AKT1—metabolic syndrome X	1.97e-05	3.51e-05	CbGpPWpGaD
